Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies

BACKGROUND: Approximately 50% of patients who receive anti-CD19 CAR-T cells relapse, and new immunotherapeutic targets are urgently needed. We recently described CD72 as a promising target in B-cell malignancies and developed nanobody-based CAR-T cells (nanoCARs) against it. This cellular therapy de...

Descripción completa

Detalles Bibliográficos
Autores principales: Temple, William C, Nix, Matthew A, Naik, Akul, Izgutdina, Adila, Huang, Benjamin J, Wicaksono, Gianina, Phojanakong, Paul, Serrano, Juan Antonio Camara, Young, Elizabeth P, Ramos, Emilio, Salangsang, Fernando, Steri, Veronica, Xirenayi, Simayijiang, Hermiston, Michelle, Logan, Aaron C, Stieglitz, Elliot, Wiita, Arun P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680002/
https://www.ncbi.nlm.nih.gov/pubmed/38007238
http://dx.doi.org/10.1136/jitc-2023-006985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680002/
https://www.ncbi.nlm.nih.gov/pubmed/38007238
http://dx.doi.org/10.1136/jitc-2023-006985

Ejemplares similares